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Abstract
Myocardial ischemia reperfusion injury (IRI) adversely affects cardiac performance and the
prognosis of patients with acute myocardial infarction. Although myocardial signal transduc-
er and activator of transcription (STAT) 3 is potently cardioprotective during IRI, the inhibito-
ry mechanism responsible for its activation is largely unknown. The present study aimed to
investigate the role of the myocardial suppressor of cytokine signaling (SOCS)-3, an intrin-
sic negative feedback regulator of the Janus kinase (JAK)-STAT signaling pathway, in the
development of myocardial IRI. Myocardial IRI was induced in mice by ligating the left ante-
rior descending coronary artery for 1 h, followed by different reperfusion times. One hour
after reperfusion, the rapid expression of JAK-STAT–activating cytokines was observed.
We precisely evaluated the phosphorylation of cardioprotective signaling molecules and the
expression of SOCS3 during IRI and then induced myocardial IRI in wild-type and cardiac-
specific SOCS3 knockout mice (SOCS3-CKO). The activation of STAT3, AKT, and ERK1/2
rapidly peaked and promptly decreased during IRI. This decrease correlated with the induc-
tion of SOCS3 expression up to 24 h after IRI in wild-type mice. The infarct size 24 h after re-
perfusion was significantly reduced in SOCS3-CKO compared with wild-type mice. In
SOCS3-CKOmice, STAT3, AKT, and ERK1/2 phosphorylation was sustained, myocardial
apoptosis was prevented, and the expression of anti-apoptotic Bcl-2 family member myeloid
cell leukemia-1 (Mcl-1) was augmented. Cardiac-specific SOCS3 deletion led to the sus-
tained activation of cardioprotective signaling molecules including and prevented myocardi-
al apoptosis and injury during IRI. Our findings suggest that SOCS3 may represent a key
factor that exacerbates the development of myocardial IRI.
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Introduction
For patients with acute myocardial infarction, an early reperfusion of the occluded coronary ar-
tery using primary percutaneous coronary intervention is the best way for limiting infarct size,
which contributes to preserving left ventricular (LV) contraction and preventing the onset of
heart failure [1, 2]. Although reperfusion can salvage the myocardium, reperfusion itself para-
doxically induces further cardiomyocyte death, which is generally known as myocardial ische-
mia reperfusion injury (IRI) [3–5]. Numerous strategies ameliorate myocardial IRI in animals.
Yet, the translation of these beneficial effects to the clinical setting has been disappointing [4,
5]. Therefore, it will be beneficial to determine the mechanisms underlying myocardial IRI and
identify novel therapeutic targets that will effectively suppress this adverse process.
Myocardial IRI induces intracellular calcium overload, oxidative stress, and inflammation,
which in turn initiate myocardial cell death, including apoptosis [3–5]. Apoptosis is a main un-
derlying mechanism of myocardial IRI and can be reversed by the activation of pro-survival
signaling pathways [6–8]. Animal studies provide many lines of evidence suggesting that myo-
cardial Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway
is a potent pro-survival signaling pathway during IRI [9–15]. Hearts from mice with a cardiac-
specific deletion of STAT3 during IRI have larger infarct size with increased numbers of apo-
ptotic cardiomyocytes and show greatly increased mortality [16]. STAT3 has been implicated
in the cardioprotection conferred by different types of preconditioning (ischemic and pharma-
cological) and postconditioning [17–24]. Recently, STAT3 has been identified in the cardio-
myocyte mitochondria, where it modulates mitochondrial respiration, regulates mitochondria-
mediated apoptosis, and inhibits the opening of mitochondrial permeability transition pores
[25, 26]. Thus, myocardial STAT3 is centrally involved in cardioprotection during IRI [27]. Al-
though the activation of STAT3 occurs transiently during myocardial IRI, the mechanism of
myocardial STAT3 inactivation during IRI is largely unknown.
The JAK-STAT pathway can be negatively regulated at several steps through distinct mech-
anisms [28, 29]. The suppressor of cytokine signaling (SOCS) family of proteins are major spe-
cific regulators of the activation of the JAK-STAT pathway [29, 30]. We and other groups have
identified SOCS proteins as cytokine-inducible intrinsic inhibitors of JAK-STAT signaling
pathways [29, 31]. Among the members of this family, SOCS1 and SOCS3 potently suppress
cytokine activity by interacting with JAK as a pseudosubstrate and inhibiting its kinase activity
[32]. The expression of SOCS3 is induced by JAK-STAT–activating cytokines and myocardial
insults such as viral infection or pressure overload [33–35]. We previously reported that the
forced expression of SOCS3 inhibits cytokine-promoted cardiomyocyte survival in vitro and
cardiac-specific transgenic expression of SOCS3 facilitates coxsackievirus-induced cardiac in-
jury in mice by inhibiting the activation of multiple signaling molecules downstream of JAK
[33–35]. In contrast, the deletion of myocardial SOCS3 in mice enhances the activation of mul-
tiple JAK-STAT signaling pathways and prevents cardiac injury and remodeling after perma-
nent coronary artery ligation [36]. Thus, the expression of SOCS3 is induced by cytokines or
myocardial insults and is centrally involved in the progression of myocardial injury. Therefore,
we hypothesized that myocardial IRI induces SOCS3 expression in the mouse heart and that
the deletion of myocardial SOCS3 would prevent IRI in mice. To test this hypothesis, we pre-
cisely determined the activation of JAK-STAT signaling pathways and expression of SOCS3
during myocardial IRI and compared induced myocardial IRI in wild-type (WT) mice versus
cardiac-specific SOCS3 knockout mice (SOCS3-CKO).
In this study, we showed that the activation of STAT3 rapidly peaked but was promptly sup-
pressed after IRI, which correlated with the induction of the expression of SOCS3 for as long as
24 h after IRI in WT mice. The cardiac-specific deletion of SOCS3 induced the sustained
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activation of cardioprotective signaling molecules including STAT3 and inhibited myocardial
apoptosis through the increased expression of anti-apoptotic Bcl-2 family member myeloid cell
leukemia-1 (Mcl-1), resulting in the prevention of myocardial IRI.
Materials and Methods
Generation of cardiac-specific SOCS3 knockout mice
We generated SOCS3flox/flox mice, which carried a SOCS3 allele flanked by loxP sites, as re-
ported previously [37]. To delete SOCS3 in the myocardium, SOCS3flox/flox mice were bred
with mice harboring a transgene encoding Cre recombinase driven by the α-myosin heavy
chain (α-MHC)-promoter [38]. All SOCS3flox/flox (WT) and SOCS3flox/flox/α-MHC-Cre
(SOCS3-CKO) mice used in this study were males (8- to 10-week-old) in a Balb/c background.
SOCS3-CKO pups were born in an expected Mendelian ratio and grew normally to adulthood.
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The study protocol
was approved by the Institutional Animal Care and Use Committee of Kurume University
School of Medicine (Permit Number: 2014-095-1). All procedures on the mice were performed
under general anesthesia with isoflurane (5% in 100% oxygen for induction; 1–2% in 100% ox-
ygen for maintenance) using an animal anesthesia machine (model TK-5, Bio Machinery,
Chiba, Japan), and all efforts were made to minimize suffering.
In vivomouse model of myocardial ischemia reperfusion injury
Animals were anesthetized with inhaled isoflurane administered using an endotracheal tube,
and positive pressure ventilation was provided with a constant-volume ventilator operating on
the Starling principle (HSE MiniVent, Harvard Apparatus GmbH). After the thoracic cavity
was opened by left thoracotomy, an 8–0 prolene suture was passed under the left anterior de-
scending (LAD) coronary artery at the inferior edge of the left atrium and tied to produce an
occlusion [39]. Ischemia was confirmed by blanching downstream of the ligation and through
persistent ST segment elevation on the electrocardiogram. Body temperature was maintained
at 37°C using a heating pad, and temperature was monitored using a rectal thermometer. After
60 min of ischemia, the ligature was released to reperfuse the LAD coronary artery. Reperfu-
sion was confirmed by the visible restoration of color in the ischemic myocardium and inver-
sion of the T wave on the electrocardiogram [39]. The chest was closed with continuous 6–0
prolene sutures. The endotracheal tube was removed after spontaneous respiration resumed. A
sham operation included all procedures, excepting the ligation of the LAD coronary artery.
Evans blue dye and triphenyltetrazolium chloride staining
Twenty-four hours after reperfusion, each mouse was anesthetized as described above, and the
chest was reopened. The LAD coronary artery was re-occluded, and the heart was perfused
with 5% Evans blue dye that indicated the normally perfused area, while the absence of staining
indicated the ischemic area [i.e., area at risk (AAR)]. The heart was excised, and the LV was cut
into five transverse slices from the apex to the base. The slices were incubated in 1% triphenyl-
tetrazolium chloride (TTC) solution at 37°C for 10 min, photographed with a digital camera
(Nikon, DXM1200, Japan), and weighed. For each image, the area lacking TTC staining (i.e.,
infarct area) and the AAR and LV areas were measured with a planimeter using Image-Pro
PLUS software (version 621.490). For each slice, the ratios of infarct to LV area and AAR to LV
area were determined and multiplied by the slice weight to calculate net infarct area and AAR
weights, respectively. The values for each slice were then summed over all slices. The total
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infarct area weight was divided by the total AAR weight (infarct area/AAR) to obtain the in-
farct size, and the total AAR weight was divided by the total LV weight (AAR/LV) to obtain the
ischemic size [36, 39].
Bio-Plex analysis
After centrifugation, serum samples were frozen and stored at −80°C until use. Serum levels of
granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-6, granulocyte macrophage
CSF (GM-CSF), and leukemia inhibitory factor (LIF) pre-ischemia and 1 h after IRI were mea-
sured on a Bio-Plex system (Bio-Rad Laboratories).
Western blot analysis
At the indicated time after reperfusion, whole LV tissues were collected and homogenized in
lysis buffer containing 25 mMHepes (pH 7.5), 1% Triton X100, 150 mMNaCl, 10% glycerol, 1
mM sodium orthovanadate, 50 mMNaF, 10 mM sodium pyrophosphate, and protease inhibi-
tor cocktail (Sigma Chemical Co.). The total cell extracts were resolved by SDS-PAGE, and
western blot analysis was performed as described previously [33, 34]. Antibodies against tyro-
sine-phosphorylated STAT3 (pY-STAT3; #9145, D3A7, rabbit monoclonal, 1:200 dilution),
serine-phosphorylated STAT3 (pS-STAT3; #9134, rabbit polyclonal, 1:200 dilution), STAT3
(#9132, rabbit polyclonal, 1:200 dilution), phosphorylated AKT (p-AKT; #4060, D9E, rabbit
monoclonal, 1:200 dilution), AKT (#9272, rabbit polyclonal, 1:200 dilution), phosphorylated
ERK1/2 (p-ERK1/2; #4370, D13.14.4E, rabbit monoclonal, 1:200 dilution), ERK1/2 (#9102,
rabbit polyclonal, 1:200 dilution), cleaved caspase-3 (#9664, 5A1E, rabbit monoclonal, 1:200
dilution), cleaved caspase-8 (#8592, D5B2, rabbit monoclonal, 1:200 dilution), Bcl-xL (#2764,
54H6, rabbit monoclonal, 1:200 dilution), Bad (#9292, rabbit polyclonal, 1:200 dilution), Bax
(#2772, rabbit polyclonal, 1:200 dilution), and Mcl-1 (#5453, D35A5, rabbit monoclonal, 1:200
dilution) were purchased from Cell Signaling Technology.
SOCS3 immunoprecipitation
SOCS3 immunoprecipitation was performed as previously described [33, 37]. In brief, at the
indicated time after reperfusion, whole LV tissues were collected, and immunoprecipitation
was conducted using a Dynabeads Protein A Immunoprecipitation Kit (#10006D, Life Tech-
nologies) according to manufacturer’s protocol. Anti-SOCS3 rabbit polyclonal antibodies
(#18391, C204 and #18395, C005) for immunoprecipitation were purchased from Immuno-Bi-
ological Laboratory, and anti-SOCS3 goat polyclonal antibodies (sc-7009, M20 and sc-7010,
S19, 1:200 dilution) for western blotting were purchased from Santa Cruz Biotechnology.
Isolation of mitochondrial and cytosolic fractions
Six hours after reperfusion, whole LV tissues were collected and homogenized using a glass tis-
sue grinder. The homogenate was centrifuged at 1,000 × g for 3 min. The pellet was suspended,
and the mitochondrial and cytosolic fractions were isolated using a Mitochondria Isolation Kit
(#89801, Thermo Scientific), according to manufacturer’s protocol. All steps were performed
at 4°C. Western blot analysis was performed using antibodies against cytochrome c (#556433,
7H8.2C12, mouse monoclonal, 1:200 dilution, BD Pharmingen), the cytosolic marker α-Tubu-
lin (#sc-8035, TU-02, mouse monoclonal, 1:200 dilution, Santa Cruz Biotechnology), and the
mitochondrial marker VDAC (#4661, D73D12, mouse monoclonal, 1:200 dilution, Cell Signal-
ing Technology).
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TUNEL assay
To detect apoptosis, a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay was performed using an In Situ Apoptosis Detection kit (Takara), according to the manu-
facturer’s protocol [33, 34]. Images were acquired at 400× magnification, and 25 random,
high-power fields from each heart sample were selected and quantified.
Immunohistochemical staining
Freshly isolated hearts were fixed in 4% paraformaldehyde (PFA), dehydrated, embedded in
paraffin and sectioned. Sections were subjected to immunohistochemical staining using a rab-
bit monoclonal antibody raised against pY-STAT3 (#9145, D3A7, 1:200 dilution, Cell Signaling
Technology) [36].
RNA extraction and real-time PCR
The total LV RNA was isolated using TRIzol (Invitrogen), as previously described [33, 34], and
1 μg of total RNA was converted into cDNA. The expression profiles of common cytokines
were obtained using the RT2 Profiler PCR array for murine common cytokines (SABioscience)
according to the manufacturer’s instructions. PCR was performed using the StepOne real-time
PCR system (Applied Biosystems). The ΔΔCt method was used to analyze the expression level
of each gene. After PCR, the dissociation curve for each gene was evaluated to exclude genes
with nonspecific amplification or undetectable expression. The expression profile of each gene
was displayed as a heat map created using MeVMultiExperiment Viewer 4.1 [36]. We also per-
formed real-time PCR assays to assess the gene expression of mouse SOCS3, Mcl1, Bcl2, and
GAPDH using the corresponding primer pairs (Applied Biosystems, #Mm00545913_s1,
#Mm00725832_s1, Mm00477631_m1, and #Mm99999915_g1, respectively) using the StepO-
nePlus Real-Time PCR System (Applied Biosystems) [36].
Echocardiography
Transthoracic echocardiographic studies were performed on mice administered light anesthe-
sia using a Vevo770 ultrasound machine (VisualSonics Inc) equipped with a 30-MHz probe.
Mice were anesthetized with isoflurane and subjected to echocardiography, as previously de-
scribed [33, 34, 36].
Statistical analysis
Data are expressed as the mean ± standard error of the mean (SE). Multiple group comparisons
were performed using one-way analysis of variance (ANOVA) followed by the Bonferroni pro-
cedure for comparison of means. Comparisons between two groups were analyzed using a two-
tailed Student’s t-test or two-way ANOVA. A p value of< 0.05 was considered to indicate
statistical significance.
Results
Rapid inductions of JAK-STAT–activating cytokines during myocardial
IRI
First, we examined the myocardial expression of common cytokines and growth factors 1 h
after reperfusion in WT mice. Using quantitative real-time PCR array containing primers for
168 genes coding for murine common cytokines and growth factors, we detected upregulation
of four genes encoding cytokines that activate the JAK-STAT signaling pathway, including
Myocardial SOCS3 and Ischemia Reperfusion Injury
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G-CSF, IL-6, and LIF (Fig 1A). Serum levels of G-CSF and IL-6 were markedly increased at 1 h
after IRI (Fig 1B). In contrast, circulating GM-CSF and LIF were undetectable level at 1 h after
IRI (data not shown).
Fig 1. Expression of JAK-STAT–activating cytokines in wild-type (WT) mice duringmyocardial IRI. (A)
mRNA was prepared from the left ventricle (LV) of WTmice 1 h after reperfusion, and real-time PCR analyses
for cytokines were performed. Values normalized to GAPDH are expressed as fold change from the values of
shammice (n = 5 per group). (B) Serum samples were collected fromWTmice at 1 h after reperfusion, and
we performed Bio-Plex analysis for cytokines (n = 5 per group). *P < 0.05 vs. pre-ischemia.
doi:10.1371/journal.pone.0127942.g001
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Rapid suppression of the phosphorylation of cardioprotective signaling
molecules during myocardial IRI
At pre-ischemia and during IRI, we performed western blot analysis to precisely determine the
phosphorylation of cardioprotective signaling molecules downstream of JAK in WTmice.
STAT3 phosphorylation was undetectable pre-ischemia, faint at 0 h, peaked 1 h after reperfu-
sion, and then decreased significantly at 3 h after reperfusion (Fig 2). AKT phosphorylation
was faint pre-ischemia, increased at 0 h, peaked 1 h after reperfusion, and then decreased sig-
nificantly at 6 h after reperfusion (Fig 2). ERK1/2 phosphorylation was faint pre-ischemia, in-
creased at 0 h, peaked 0.3 h after reperfusion, and then decreased significantly at 3 h after
reperfusion (Fig 2). Thus, the IRI-induced activation of cardioprotective signaling molecules
decreased rapidly after reperfusion, suggesting a mechanism that inhibits the activities of car-
dioprotective signaling molecules during IRI.
Confirmation of myocardial-specific SOCS3 deletion in SOCS3-CKO
mice
For systemic induction of SOCS3 expression, we intraperitoneally injected lipopolysaccharide
(LPS, 20 mg/kg) into mice and performed real-time PCR of SOCS3 in the heart and liver. We
confirmed that SOCS3 mRNA expression was induced in LPS-injected hearts fromWTmice,
and was markedly reduced in LPS-injected hearts from SOCS3-CKOmice (Fig 3). In contrast,
the upregulation of SOCS3 expression after LPS injection was comparable between WT and
SOCS3-CKO liver (Fig 3). Thus, the deletion of SOCS3 via the α-MHC-promoter Cre recom-
binase is specific to the myocardium. Echocardiography revealed no difference in left ventricu-
lar function or wall thickness in SOCS3-CKO mice when compared with WTmice (S1 Fig).
Hematoxylin/eosin and Mallory-Azan staining of hearts from 10-week-old SOCS3-CKOmice
revealed no evidence of necrosis, cardiac fibrosis, or hypertrophy (S2 Fig). Thus, histological
examination and echocardiography indicated that global cardiac structure and function were
comparable between SOCS3-CKOmice and WTmice.
Sustained SOCS3 protein expression during myocardial IRI
SOCS3 protein is difficult to detect due to its degradation through the ubiquitin–proteasome
system [40]. To facilitate the detection of SOCS3 protein, we conducted immunoprecipitation
and western blot analysis. The expression of SOCS3 protein was undetectable pre-ischemia, in-
creased at 1 h and peaked 3 h after reperfusion, and was sustained for 24 h in WT mice (Fig
4A). In the SOCS3-CKOmice, SOCS3 protein expression was not detected 3 h after reperfu-
sion (Fig 4A). Real-time PCR also revealed that, at 3 h after IRI, the expression of SOCS3
mRNA was increased in WTmice and was markedly reduced in SOCS3-CKOmice (Fig 4B).
Reduced infarct size and preserved LV contraction in SOCS3-CKOmice
after IRI
We employed Evans blue and TTC double staining 24 h after reperfusion to determine the in-
farct area; AAR, which indicates the ischemic area; and the normally perfused area of LV. In-
farct size and ischemic size were defined, respectively, as the weight ratios of infarct area to
AAR and AAR to LV. Infarct size was significantly reduced in the hearts of SOCS3-CKO com-
pared with WTmice, even though the ischemic size of the two groups were comparable (Fig
5A). Echocardiographic assessment revealed that the percent fractional shortening was greater
and the LV end-systolic dimension was smaller in SOCS3-CKO than in WTmice (Fig 5B).
The LV end-diastolic dimension, interventricular septum thickness, and posterior LV wall
Myocardial SOCS3 and Ischemia Reperfusion Injury
PLOS ONE | DOI:10.1371/journal.pone.0127942 May 26, 2015 7 / 25
Fig 2. Activation of cardioprotective signaling molecules in wild-type (WT) mice duringmyocardial
IRI. Total cell lysates were prepared from the left ventricle of WTmice at the indicated times after reperfusion.
Blots were probed using antibodies against tyrosine-phosphorylated STAT3 (pY-STAT3), STAT3,
phosphorylated AKT (p-AKT), AKT, phosphorylated ERK1/2 (p-ERK1/2), and GAPDH. The graphs represent
quantitative differences in expression between the ratios of pY-STAT3 to STAT, p-AKT to AKT, and p-ERK1/
2 to ERK1/2 (n = 6 per group). *P < 0.05 vs. pre-ischemia, §P < 0.05 vs. 1 h (pY-STAT3 and p-AKT) or 0.3 h
(p-ERK1/2) after reperfusion. AU, arbitrary units; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IRI,
ischemia reperfusion injury.
doi:10.1371/journal.pone.0127942.g002
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thickness were comparable between SOCS3-CKO andWT mice 24 h after reperfusion (S1
Fig). During the chronic phase after reperfusion, the LV end-systolic dimension was gradually
(not significantly) increased and the LV end-diastolic dimension was significantly increased in
WTmice (Fig 6). In contrast, percent fractional shortening, LV end-systolic dimension, and
Fig 3. Confirmation of myocardial-specific SOCS3 deletion in SOCS3-CKOmice.mRNAwas prepared
from the hearts and livers of wild-type (WT) mice 3 h after lipopolysaccharide (LPS) injection, and real-time
PCR analyses for SOCS3 were performed. Values normalized to GAPDH are expressed (n = 5 per group).
*P < 0.05 vs. WT pre-injection, §P < 0.05 vs. WT LPS injection.
doi:10.1371/journal.pone.0127942.g003
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Fig 4. Early and sustained expression of SOCS3 protein duringmyocardial IRI. (A) Total cell lysates
(TCL) were prepared from the left ventricle of wild-type (WT) and SOCS3-CKOmice at the indicated times
after reperfusion and were immunoprecipitated with anti-SOCS3 antibodies. The immunoprecipitates and
total cell lysates were subjected to western blotting and probed with antibodies against SOCS3 and GAPDH,
respectively. The graphs represent the time course expression of SOCS3 protein in WTmice after
reperfusion (left) and the quantitative difference betweenWT and SOCS3-CKOmice 3 h after reperfusion
(right; n = 5 per group). *P < 0.05 vs. WT pre-ischemia. §P < 0.05 vs. WT 3 h after reperfusion. AU indicates
Myocardial SOCS3 and Ischemia Reperfusion Injury
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arbitrary units; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IRI, ischemia reperfusion injury. (B)
Real-time PCR analysis for SOCS3mRNA expression in mouse hearts pre-ischemia or 3 h after reperfusion
(n = 5 for each group). *P < 0.05 vs. pre-ischemia.
doi:10.1371/journal.pone.0127942.g004
Fig 5. Reduced infarct size and preserved left ventricular systolic function after IRI in SOCS3-CKO
mice. (A) Representative images of Evans blue and triphenyltetrazolium chloride (TTC) staining in wild-type
(WT) and SOCS3-CKOmice 24 h after reperfusion (top) (n = 8 per group). The infarct size of the left ventricle
(LV) was expressed as a percentage of the area at risk (AAR) of each group (left). The graphs show
quantification of AAR/LV and infarct area/AAR. *P < 0.05 vs. WTmice. (B) Echocardiography was performed
pre-ischemia and 24 h after reperfusion (n = 8 per group). Pooled data for echocardiographic measurements
in WT and SOCS3-CKOmice. *P < 0.05 vs. WTmice. FS indicates fractional shortening; LVESD, left
ventricular end systolic dimension; IRI, ischemia reperfusion injury.
doi:10.1371/journal.pone.0127942.g005
Myocardial SOCS3 and Ischemia Reperfusion Injury
PLOS ONE | DOI:10.1371/journal.pone.0127942 May 26, 2015 11 / 25
LV end-diastolic dimension were preserved in SOCS3-CKOmice (Fig 6). The interventricular
septum was significantly thicker in SOCS3-CKOmice than in WTmice from day 7 to 28 after
reperfusion (Fig 6).
Fig 6. Echocardiography measurements in wild-type (WT) and cardiac-specific SOCS3-CKOmice
during the chronic phase. Echocardiography was performed at pre-ischemia and from day 1 to day 28 after
reperfusion (n = 8 per group). Pooled data for echocardiographic measurements in WT and SOCS3-CKO
mice. *P < 0.05 vs. WTmice. FS indicates fractional shortening; LVESD, left ventricular end systolic
dimension; LVEDD, left ventricular end diastolic dimension; IVST, interventricular septum thickness; PWT,
posterior left ventricular wall thickness.
doi:10.1371/journal.pone.0127942.g006
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Sustained activation of cardioprotective signaling molecules in
SOCS3-CKOmice during IRI
Next, we performed western blot analysis to compare the activation of cardioprotective signal-
ing pathways, including STAT3, AKT, and ERK1/2 during IRI in WT and SOCS3-CKOmice.
STAT3 phosphorylation levels were similar between SOCS3-CKO andWTmice 1 h after re-
perfusion (Fig 7A). STAT3 phosphorylation in WTmice decreased from 3 h to 24 h after re-
perfusion (Fig 7A). In contrast, STAT3 phosphorylation levels peaked in SOCS3-CKO mice by
1 h and were sustained until 6 h after reperfusion, and STAT3 phosphorylation was significant-
ly higher than in WTmice 24 h after reperfusion (Fig 7A). Immunohistochemical staining re-
vealed that, at 6 h post-IRI, the number of pY-STAT3–positive cells was significantly greater in
hearts from SOCS3-CKO mice than in those fromWTmice (Fig 7B). AKT and ERK1/2 phos-
phorylation levels in SOCS3-CKOmice increased similarly 1 h after reperfusion compared
with their levels in WT mice, and they were significantly higher than those of WT mice up to 6
h after reperfusion (Fig 7A). Thus, the IRI-induced activation of cardioprotective signaling
molecules was sustained for a longer duration in SOCS3-CKO mice than in WTmice.
Reduction of myocardial apoptosis in SOCS3-CKOmice after IRI
The apoptosis of cardiomyocytes is centrally involved in the development of myocardial injury
after IRI [6–8]. We performed TUNEL assay to measure the number of apoptotic cells 6 h after
reperfusion. The number of TUNEL-positive cells was markedly reduced in SOCS3-CKO com-
pared with WTmice (Fig 8A). Cytochrome c release from the mitochondria into the cytosol
was decreased after IRI in SOCS3-CKOmice compared with WTmice (Fig 8B). Western blot
analysis revealed that, after IRI, expression of cleaved caspase 8 was comparable between WT
and SOCS3-CKOmice, while the expression of cleaved caspase 3 was lower in hearts from
SOCS3-CKO mice than in those fromWTmice (Fig 8C). Because activation of STAT3 at ser-
ine 727 has been indicated to regulate a metabolic function in mitochondria and act in the reg-
ulation of survival and apoptosis [41], we used western blotting to measure pS-STAT3. We
found that, after IRI, the expression of pS-STAT3 was greater in hearts from SOCS3-CKO
mice than in hearts fromWTmice (Fig 8C). We determined the expression levels of mitochon-
dria-associated pro- and anti-apoptotic molecules in the hearts of SOCS3-CKO and WTmice
6 h after reperfusion. Although the expression of anti-apoptotic Bcl-2 and Bcl-xL and pro-apo-
ptotic Bad and Bax expression were comparable between SOCS3-CKO and WTmice, Mcl-1
(an anti-apoptotic member of the Bcl2 family) was expressed at a significantly higher level in
SOCS3-CKO mice than in WT mice 6 h after reperfusion (Fig 9A). Real-time PCR also re-
vealed that expression of Mcl1 mRNA, but not Bcl2 mRNA, was greater in SOCS3-CKOmice
than in WTmice after reperfusion (Fig 9B).
Augmentation of antioxidant gene expression and reduction of pro-
inflammatory gene expression
Because STAT3 is involved in the regulation of oxidative stress and inflammation that may af-
fect apoptosis during myocardial IRI, we examined PCR array analysis for indications of oxida-
tive stress and inflammation during myocardial IRI. The expression of some antioxidant
enzymes, including glutathione peroxidase (Gpx)-3, Gpx4, Gpx7, peroxiredoxin (Prdx)-2, and
Prdx4 was significantly lower in SOCS3-CKO mice than in WT mice after reperfusion (Fig
10). The expression of pro-inflammatory cytokines, including interferon-γ, tumor necrosis fac-
tor-α (TNFα), and IL-1β were significantly lower in SOCS3-CKO than in WT mice, and the
Myocardial SOCS3 and Ischemia Reperfusion Injury
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Fig 7. (A) Sustained activation of cardioprotective signalingmolecules in SOCS3-CKOmice during
IRI.Western blot analysis of total cell lysates prepared from the left ventricle of WT or SOCS3-CKOmice at
the indicated times after reperfusion. The blots were probed using antibodies against tyrosine-
phosphorylated STAT3 (pY-STAT3), STAT3, phosphorylated AKT (p-AKT), AKT, phosphorylated ERK1/2 (p-
ERK1/2), and GAPDH. The graphs represent quantitative differences in the ratios of the expression of
Myocardial SOCS3 and Ischemia Reperfusion Injury
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expression of anti-inflammatory cytokines (including IL-24 and IL-27, but not IL-10) were
greater in SOCS3-CKO than in WTmice after reperfusion (Fig 11).
Discussion
In the present study, we attempted to determine the role of myocardial SOCS3, an intrinsic
negative feedback regulator of the JAK-STAT pathway-activating cytokines, in the inhibitory
mechanism of cardioprotective signaling molecules during myocardial IRI in mice. For this
purpose, we determined the activation kinetics of cardioprotective signaling molecules STAT3,
AKT, and ERK1/2. The activation of STAT3 peaked rapidly but was promptly suppressed after
IRI, which correlated with the induction of SOCS3 expression for as long as 24 h after IRI in
WT mice. Cardiac-specific deletion of SOCS3 induced the sustained activation of cardioprotec-
tive signaling molecules and inhibited myocardial apoptosis through the increased expression
of anti-apoptotic Mcl-1, resulting in the prevention of myocardial IRI. These findings suggest
that myocardial SOCS3 suppresses the activation of cardioprotective signaling molecules dur-
ing IRI and that SOCS3 may be centrally involved in the development of myocardial IRI.
Mechanism of inhibition of cardioprotective signaling molecules during
myocardial IRI
Many lines of evidence suggest that STAT3 is one of the major cardioprotective signaling mole-
cules against myocardial IRI [9–16]. However, previous reports do not focus on the inhibitory
mechanism against the activation of STAT3 during myocardial IRI. McCormick et al. showed
the transient activation of STAT3 within 2 h after reperfusion in an in vivo rat model of myo-
cardial IRI; they suggested that a negative feedback mechanism inhibits the full activation of
STAT3 [27]. In the present study, we precisely examined the activation kinetics of the cardio-
protective signaling molecules STAT3, AKT, and ERK1/2 for up to 24 h after reperfusion. The
levels of STAT3, AKT, and ERK1/2 phosphorylation were comparable between WT and
SOCS3-CKO mice within 1 h after reperfusion (Fig 7), suggesting that the inhibitory mecha-
nism was not active during this period. Thus, SOCS3 protein was not significantly induced
until 1 h after reperfusion (Fig 4). From 3 to 24 h after reperfusion, the time course of SOCS3
protein expression paralleled the sustained reduction of STAT3 phosphorylation. Because the
SOCS3 promoter contains a functionally important STAT3-binding elements [42], the induc-
tion of SOCS3 protein expression was dependent on the activation of STAT3 after reperfusion.
Thus, SOCS3 is a STAT3-induced negative feedback regulator of the activation of STAT3 dur-
ing myocardial IRI.
In contrast to the enhanced and prolonged phosphorylation of STAT3, the enhanced and
prolonged phosphorylation of AKT and ERK1/2 is mild during myocardial IRI in SOCS3-CKO
mice (Figs 2 and 7). It is well known that STAT3 is a specific downstream signaling molecule
of JAK and is mainly activated by JAK-STAT–activating cytokines [28, 29]. Meanwhile, AKT
and ERK1/2 are activated not only by JAK-STAT–activating cytokines, but also by a variety of
cytokines and growth factors that do not activate JAK [43, 44]. We previously reported that the
forced expression of SOCS3 completely inhibits the LIF-induced activation of AKT, ERK1/2,
pY-STAT3 to STAT3, p-AKT to AKT, and p-ERK1/2 to ERK1/2 (n = 6 per group). *P < 0.05 vs. WTmice. AU,
arbitrary units; IRI, ischemia reperfusion injury. (B) Immunostaining of tyrosine-phosphorylated STAT3
(pY-STAT3) in hearts pre-ischemia or 3 h after reperfusion (n = 5 for each group). Representative
photographs of the hearts from each group are shown. Values are expressed as the percentage of
pY-STAT3–positive cells in the hearts pre-ischemia or 6 h after reperfusion. *P < 0.05 vs. pre-ischemia.
Scale bar = 100 μm. AU = arbitrary units.
doi:10.1371/journal.pone.0127942.g007
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Fig 8. Reduction of apoptosis andmitochondrial cytochrome c release in SOCS3-CKOmice during
IRI. (A) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays of hearts from wild-
type (WT) or SOCS3-CKOmice 6 h after reperfusion (n = 5 per group). Representative images of the
ischemic areas of hearts from each group. The graph shows the percentage of TUNEL-positive cells.
*P < 0.05 vs. WT sham, §P < 0.05 vs. WT IRI. (B) The cytosolic (Cyto) and mitochondrial (Mito) fractions
were prepared from the left ventricles of WT or SOCS3-CKOmice 6 h after reperfusion and subjected to
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and STAT3 in the cardiomyocytes [33]. Because SOCS3 is a JAK binding protein and strongly
suppresses JAK kinase activity [28, 29], SOCS3 is able to inhibit the activation of all JAK down-
stream signaling molecules, including AKT and ERK1/2, but is not able to inhibit the activation
of AKT and ERK1/2 by cytokines and growth factors that do not utilize JAK. A wide range of
cytokines and growth factors are induced during myocardial IRI [4, 5]. SOCS3 is able to inhibit
the activation of AKT and ERK1/2 by JAK-STAT–activating cytokines, but is not able to inhib-
it the activation of AKT and ERK1/2 by cytokines and growth factors that do not utilize JAK
during IRI. This is the reason for the mild enhancement and prolongation of AKT and ERK1/2
activation during myocardial IRI in SOCS3-CKOmice. Further, Ruan et al. determined the
role of myocardial phosphatase and tensin homolog on chromosome ten (PTEN), an impor-
tant negative regulator of the PI3 kinase-AKT pathway, in myocardial IRI [45]. They demon-
strated greater activation of AKT and ERK1/2 and reduced myocardial IRI in cardiac-specific
PTEN knockout mice [45]. Thus, other inhibitors such as PTEN may contribute to the inhibi-
tory mechanism of AKT and ERK1/2 activation during myocardial IRI.
Inhibition of IRI-induced myocardial apoptosis by cardiac-specific
deletion of SOCS3
Apoptosis plays a major role in the development of myocardial IRI [46]. For example, animal
studies have shown that myocardial STAT3 is a potent anti-apoptotic, pro-survival signaling
molecule during IRI [9–16]. Consistent with previous reports, we show here that the cardiac-
specific deletion of SOCS3 induced a sustained activation of STAT3 and reduced myocardial
apoptosis that prevented IRI in mice. However, the expression levels of anti-apoptotic Bcl2 and
Bcl-xL and pro-apoptotic Bad and Bax were comparable between WT and SOCS3-CKOmice,
even though STAT3 regulates their expression [16]. Because SOCS3 inhibits multiple cytokines
and growth factors that utilize the JAK kinase to transduce their signals [28–30], the deletion
of SOCS3 may enhance the action of multiple cytokines and growth factors. Furthermore, the
deletion of SOCS3 may enhance multiple JAK downstream signaling pathways including
STAT3, AKT, and ERK1/2. This may explain the comparable expression levels of molecules in-
volved in apoptosis between WT and SOCS3-CKO mice. Among molecules involved in apo-
ptosis, we found that the expression of the anti-apoptotic Bcl2 family member Mcl-1 was
significantly upregulated in SOCS3-CKOmice compared with WTmice. Bolli et al. reported
that ischemic preconditioning increased the expression of Mcl-1 in WT mouse hearts, which
was absent in cardiac-specific STAT3 knockout mice, suggesting that Mcl-1 is a STAT3 target
gene [47]. The loss of Mcl-1 expression promotes the induction of apoptosis in a variety of
other tissues [48]. Recently, Wang et al. reported that cardiac-specific Mcl-1 knockout mice ex-
hibit myocardial cell apoptosis and mitochondrial abnormalities leading to dilated cardiomy-
opathy [49], which indicates a critical role for Mcl-1 in the prevention of myocardial cell
apoptosis. Taken together with our present findings, we suggest that the upregulated
western blotting using an antibody against cytochrome c. The cytosolic marker α-tubulin and the
mitochondrial marker VDAC served as internal controls for WTmice (n = 6 per group). The graph represents
quantitative differences in cytochrome c expression. *P < 0.05 vs. WT sham, §P < 0.05 vs. WT IRI. AU,
arbitrary units; IRI, ischemia reperfusion injury. (C) Total cell lysates were prepared from the left ventricles of
wild-type (WT) or SOCS3-CKOmice pre-ischemia or 6 h after reperfusion, and western blots were probed
with antibodies raised against cleaved caspase 8, cleaved caspase 3, and serine-phosphorylated STAT3
(pS-STAT3). The graphs represent quantitative differences in expression among cleaved caspase 8, cleaved
caspase 3, and PS-STAT3 (n = 5 per group). §P < 0.05 vs. WT pre-ischemia, *P < 0.05 vs. WT 6 h after IRI.
AU, arbitrary units; IRI, ischemia reperfusion injury.
doi:10.1371/journal.pone.0127942.g008
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Fig 9. (A) Increased expression of anti-apoptotic Mcl-1 after IRI in SOCS3-CKOmice. Total cell lysates
were prepared from the left ventricles of wild-type (WT) or SOCS3-CKOmice pre-ischemia or 6 h after
reperfusion, and western blots were probed with antibodies raised against Mcl-1, Bcl-xL, Bcl-2, Bad, and Bax.
The graphs represent quantitative differences in expression among Mcl-1, Bcl-xL, Bcl-2, Bad, and Bax (n = 5
per group). *P < 0.05 vs. WT IRI. AU, arbitrary units; IRI, ischemia reperfusion injury. (B) Real-time PCR
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analysis of Mcl1 and Bcl2 mRNA expression in the hearts pre-ischemia and 3 h after reperfusion (n = 5 for
each group). *P < 0.05 vs. WT after reperfusion.
doi:10.1371/journal.pone.0127942.g009
Fig 10. Expression of genes related to oxidative stress during myocardial IRI.mRNAwas prepared from the left ventricles of WT or SOCS3-CKOmice
after reperfusion and subjected to real-time PCR analysis regarding the indicated genes. Values normalized against glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) are expressed as fold change from the values of shammice (n = 5 for each group). *P<0.05 versusWT sham. Gpx = glutathione
peroxidase; Prdx = peroxiredoxin; HO = heme oxygenase; Sod = superoxide dismutase.
doi:10.1371/journal.pone.0127942.g010
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expression of Mcl-1 during IRI may play an important role in preventing myocardial apoptosis
in SOCS3-CKOmice.
It is well known that oxidative stress and inflammation are centrally involved in the myocar-
dial damage caused by myocardial IRI. For example, Dabkowski et al. reported that mitochon-
dria-specific transgenic overexpression of the antioxidant enzyme Gpx4 attenuates myocardial
damage during IRI [50]. Suzuki et al. reported that the overexpression of IL-1 receptor antago-
nist attenuates myocardial apoptosis during IRI [51]. In the present study, some antioxidant
Fig 11. Expression of pro-inflammatory and anti-inflammatory cytokine genes during myocardial IRI.mRNAwas prepared from the left ventricles of
WT or SOCS3-CKOmice after reperfusion and subjected to real-time PCR analysis regarding the indicated genes. Values normalized against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are expressed as fold change from the values of shammice (n = 5 for each group). *P<0.05 versus
WT sham. IL = interleukin; IFN = interferon; TNF = tumor necrosis factor.
doi:10.1371/journal.pone.0127942.g011
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enzymes (including Gpx4) were increased and main pro-inflammatory cytokines (including
IL-1β were decreased in SOCS3-CKOmice after reperfusion. These increases of antioxidant
enzymes and reductions of pro-inflammatory cytokines may contribute to the attenuation of
myocardial apoptosis during IRI in SOCS3-CKOmice.
SOCS3 is a therapeutic target for myocardial IRI
We previously reported that the expression of SOCS3 mRNA is rapidly induced (within 30
min) in cytokine-stimulated cardiomyocytes or pressure-overloaded mouse hearts, suggesting
that SOCS3 is an early response gene [33]. In the present study, we detected the expression of
SOCS3 protein 3 h after reperfusion, which unexpectedly persisted for 24 h. This SOCS3 pro-
tein expression paralleled the sustained reduction of STAT3 activation during IRI. Further-
more, we demonstrated previously that the adenoviral expression of SOCS3 completely
inhibits the cytokine-induced activation of STAT3, AKT, and ERK1/2 in cardiomyocytes [33,
34]. Thus, SOCS3 is a potent inhibitor of the JAK-STAT signaling pathway, is persistently ex-
pressed during IRI, and suppresses IRI-induced STAT3 activation. Therefore, because cardiac-
specific deletion of SOCS3 prevented myocardial apoptosis and dysfunction during IRI, myo-
cardial SOCS3 may represent a key factor that exacerbates the development of IRI.
Resistance to cytokines limits their intrinsic efficacy. We showed previously that SOCS3
confers resistance to cytokines (e.g., interferon, leptin, and cardiotrophin-1) that utilize the
JAK-STAT pathway to transduce their signals [52–54]. Despite the strong experimental evi-
dence supporting a real cardioprotective effect of JAK-STAT–activating cytokines, including
erythropoietin and G-CSF, in animal models of myocardial IRI, clinical trials have failed to
translate a benefit into the clinical setting [55]. In the present study, we showed that the SOCS3
protein was rapidly and persistently expressed during myocardial IRI. In addition SOCS3 is in-
duced not only by myocardial insults, but also by administered cytokine itself. Therefore, IRI-
induced SOCS3 may reduce the effect of cytokine therapy in patients with acute myocardial in-
farction. Small-molecule antagonists of SOCS3 or tissue-specific vector delivery of SOCS3 in-
hibitor may represent clinically valuable strategies to enhance the protective effect of both
endogenous and administered JAK-STAT–activating cytokines during myocardial IRI.
In the present study, we show that activation of the cardioprotective signaling molecules
STAT3, AKT, and ERK1/2 rapidly peaked and was promptly suppressed during IRI. This sup-
pression paralleled the induction of SOCS3 expression after the onset of IRI in WT mice. In
SOCS3-CKO mice, STAT3, AKT, and ERK1/2 phosphorylation was sustained, myocardial ap-
optosis and injury were prevented, and the expression of the anti-apoptotic Bcl-2 family mem-
ber Mcl-1 was augmented. Thus, the deletion of myocardial SOCS3 induced the sustained
activation of cardioprotective signaling molecules including STAT3 and prevented myocardial
apoptosis and injury during IRI. Our findings suggest that SOCS3 may represent a key factor
that exacerbates the development of myocardial IRI.
Supporting Information
S1 Fig. Echocardiography of wild-type (WT) and cardiac-specific suppressor of cytokine
signaling-3 knockout (SOCS3-CKO) mice. Echocardiography was performed pre-ischemia
and 24 h after reperfusion (n = 8 per group). The LV end-diastolic dimension (LVEDD), inter-
ventricular septum thickness (IVST), and posterior left ventricular wall thickness (PWT) were
comparable between the two groups at 24 h after reperfusion.
(TIF)
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S2 Fig. Heart sections from 10-week-old wild-type (WT) and SOCS3-CKOmice stained
with hematoxylin/eosin and Mallory-Azan are shown.
(JPG)
S3 Fig. Full unedited blots for Fig 2. Blots were probed using antibodies against tyrosine-
phosphorylated STAT3 (pY-STAT3), STAT3, phosphorylated AKT (p-AKT), AKT, phosphor-
ylated ERK1/2 (p-ERK1/2), and GAPDH.
(JPG)
S4 Fig. Full unedited blots for Fig 4. Blots were probed using antibodies against SOCS3 and
GAPDH.
(JPG)
S5 Fig. Full unedited blots for Fig 7. Blots were probed using antibodies against tyrosine-
phosphorylated STAT3 (pY-STAT3), STAT3, phosphorylated AKT (p-AKT), AKT, phosphor-
ylated ERK1/2 (p-ERK1/2), and GAPDH.
(JPG)
S6 Fig. Full unedited blots for Fig 8. Blots were probed using antibodies against cytochrome
c, α-tubulin, VDAC, GAPDH, cleaved caspase 8, cleaved caspase 3, serine-phosphorylated
STAT3 (pS-STAT3), and STAT3.
(JPG)
S7 Fig. Full unedited blots for Fig 9. Blots were probed using antibodies against myeloid cell
leukemia-1 (Mcl-1), Bcl-xL, Bcl-2, Bad, Bax, and GAPDH.
(JPG)
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